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CD137 (4-1BB/tnfrsf9) has been shown to co-stimulate T 
cells. However, agonistic anti-CD137 monoclonal antibody 
(mAb) treatment can suppress CD4
＋ T cells, ameliorating 
autoimmune diseases, whereas it induces activation of 
CD8
＋ T cells, resulting in diverse therapeutic activity in can-
cer, viral infection. To investigate the CD137-mediated T cell 
suppression mechanism, we examined whether anti-CD137 
mAb treatment could affect CD11b
＋Gr-1
＋ myeloid-derived 
suppressor cells (MDSCs). Intriguingly, anti-CD137 mAb in-
jection significantly increased CD11b
＋Gr-1
＋ cells, peaking 
at days 5 to 10 and continuing for at least 25 days. 
Furthermore, this cell population could suppress both CD8
＋ 
T cells and CD4
＋ T cells. Thus, this study demonstrated that, 
for the first time, anti-CD137 mAb treatment could induce 
CD11b
＋Gr-1
＋ MDSCs under normal conditions, suggesting 
a possible relationship between myeloid cell induction and 
CD137-mediated immune suppression.
[Immune Network 2010;10(3):104-108]
CD137  (4-1BB/tnfrsf9),  a  member  of  tumor  necrosis  factor 
(TNF)-receptor family, is a co-stimulatory molecule for T cell 
activation.  Treatment  with  the  agonistic  anti-CD137  mono-
clonal antibody (mAb) in vitro stimulates CD8
＋ T cells and, 
to a lesser extent, CD4
＋ T cells. However, in vivo signaling 
leads  to  CD4
＋  T  cell  deletion  and  suppression,  although 
CD8
＋ T cells are massively expanded and activated (1). This 
controversy  ensures  that  in  vivo a g o n i s t i c  a n t i - C D 1 3 7  m A b  
treatment induces antitumor (2,3) and antiviral immunity (4) 
through Ag-specific CD8
＋ T cell activation while suppressing 
Ag-specific CD4
＋ T cells and antibody responses (5) that re-
sult in the amelioration of autoimmune diseases (6-10) and 
chronic  graft  versus  host  diseases  (11).
    In a recent study that aimed to clarify the mechanism of 
this  phenomenon,  Ag-dependent  and  CD137-mediated  in-
duction of a new cell population, CD11c
＋CD8
＋ T cells, was 
identified in a rheumatoid arthritis model and was shown to 
b e  c r u c i a l  f o r  i n d u c i n g  s u p p r e s s i o n  o f  A g - s p e c i f i c  C D 4
＋ T  
cells by interferon gamma (IFNγ) and indoleamine 2,3-diox-
ygenase (IDO) (9). Furthermore, the emergence of CD11c
＋
CD8
＋ T cells by anti-CD137 mAb treatment was also reported 
in other disease models, such as virus infection, experimental 
autoimmune uveoretinitis and tumors (12,13). However, the 
mechanisms responsible for the suppression mediated by an-
ti-CD137 mAb treatment are still unclear. Therefore, to under-
stand the suppressive outcomes of CD137 stimulation, the un-
defined changes in cell types and functions induced by an-
ti-CD137  mAb  treatment  need  to  be  further  examined. 
    A  recent  study  showed  that  interactions  between  CD137 
and CD137L have limited roles in myelopoiesis and the devel-
opment of dendritic cells (14), suggesting the possibility that 
CD137 signaling is involved in myeloid cell development and 
differentiation. Furthermore, it has been shown that in vivo 
anti-CD137 mAb treatment in a spontaneous lupus-like syn-
drome model induces  the expansion of  macrophage/granu-
locyte population in an IFNγ-dependent manner (6). How-
ever, it is still unclear whether anti-CD137 mAb treatment af-Myeloid-derived Suppressor Cells Induced by CD137 Stimulation
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Figure 1. Agonistic anti-CD137 Ab treatment increases CD11b
＋Gr-1
＋ cells in spleen. Naïve BALB/c mice were intraperitoneally (i.p) injected 
with 300μg of anti-CD137 Ab (3H3) or rIgG control Ab. Five days later, the percentage (A) and number (B) of CD8




＋ T cells (CD3ε
−CD4
＋), B cells (B220
＋CD3ε




＋ cells and CD11b
＋Gr-1
＋ cells in splenocytes
were examined (n=3∼4/group). *p＜0.05, **p＜0.005, 
†p＜0.001. Data are representative of at least three separate experiments.
fects  the  generation  of  immunosuppressive  myeloid  cells.
  In this study, we investigated the role of CD137 stimulation 
in the myelopoiesis and immune cell expansion by injecting 
300μg  o f  a g o n i s t i c  a n t i - C D 1 3 7  m A b  ( 3 H 3 )  o r  r I g G  c o n t r o l 
Ab to naïve BALB/c mice. Five days later, the changes in per-
centage  and  number  of  diverse  cell  populations,  including 
CD8
＋ T cells, CD4





＋ myeloid cells in splenocytes were an-
alyzed  using  flow  cytometry.  As  a  result,  anti-CD137  mAb 
treatment significantly increased both the percentage and real 
numbers of CD8
＋ T cells compared to the control Ab treat-
ment (Fig. 1). However, it decreased the percentage of CD4
＋ 
T cells, B cells and NK cells, as previously reported (15), but 
only minimally changed the numbers of cells. As shown in 
a  previous  report  (9),  anti-CD137  mAb  treatment  increased 
CD11c
＋CD8α
＋ cells and also significantly increased CD11b
＋
Gr-1
＋ cells both in percentage and real number (p＜0.001), 
suggesting that myelopoiesis of CD11b
＋Gr-1
＋ cells could be 
influenced  by  CD137  stimulation.
    Recent studies suggested that CD11b
＋Gr-1
＋ myeloid- de-
rived suppressor cells (MDSCs) in mice have been shown to 
accumulate in diverse pathological conditions including can-
cer, infectious diseases, sepsis, trauma, bone marrow trans-
plantation and some autoimmune diseases, as well as inhibit 
the function of T cells (16). Therefore, we examined whether 
increased CD11b
＋Gr-1
＋ cells by anti-CD137 mAb treatment 
could induce characteristics of MDSCs. First, we checked the 
kinetic changes in CD11b
＋Gr-1
＋ cells after anti-CD137 mAb 
treatment. Single administration of 3H3 led to a significant in-
crease in the CD11b
＋Gr-1
＋ cell population of splenocytes 5 
days after treatment and continued for at least 25 days (Fig. 
2A). The number of CD11b
＋Gr-1
＋ cells also increased by the Myeloid-derived Suppressor Cells Induced by CD137 Stimulation
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Figure 2. The kinetics of splenic CD11b
＋Gr-1
＋ cells due to anti-CD137 Ab treatment. The kinetic changes in percentage (A) and number (B) 
of splenic CD11b
＋Gr-1
＋ cells were measured after 300μg of anti-CD137 Ab i.p injection.
treatment of anti-CD137 mAb and peaked at day 10 (Fig. 2B). 
Collectively, these data suggested that anti-CD137 mAb treat-




    Next, to investigate that the CD11b
＋Gr-1
＋ cells induced by 
anti-CD137 mAb treatment had suppressive activity similar to 
MDSCs, the effect of CD137 stimulation-induced CD11b
＋Gr-1
＋ 
cells on Ag-specific T cell proliferation was tested. As a result, 
OVA  Ag-specific  proliferation  of  DO11.10  splenocytes  and 
OT-I  splenocytes  was  down-regulated  in  a  dose-dependent 
manner  by  CD11b
＋Gr-1
＋ c e l l s  i s o l a t e d  a t  5  d a y  a f t e r  a n -
ti-CD137 mAb treatment, as compared to CD11b
＋Gr-1
＋ cells 
obtained from naïve mice (Fig. 3A and B). Furthermore, this 
suppressive  activity  was  also  shown  in  CD11b
＋Gr-1
＋ c e l l s  
isolated at 25 day after anti-CD137 mAb injection (Fig. 3C and 
D).  Collectively,  we  concluded  that  CD137  stimulation  dra-
matically induced CD11b
＋Gr-1
＋ cells, which suppressed both 
CD8
＋ a n d  C D 4
＋ T  c e l l s .
  In this study, we demonstrated that, for the first time, an-
ti-CD137 mAb treatment significantly induced CD11b
＋Gr-1
＋ 
MDSCs. The presence of this population might explain a nov-
el mechanism of CD137 stimulation-mediated suppression of 
T cells. Thus, to thoroughly understand the diverse outcome 
of anti-CD137 mAb treatment, the nature of this population 
needs  to  be  clarified  more  precisely. 
    We  measured  CD137  expression  on  naïve  CD11b
＋Gr-1
＋ 
cells  to  investigate  that  anti-CD137  mAb  would  act  directly 
on myeloid cells. However, CD137 expression was not ob-
served on CD11b
＋Gr-1
＋ cells from spleen and bone marrow 
(data not shown), suggesting that anti-CD137 mAb treatment 
might  indirectly induce the increase of CD11b
＋Gr-1
＋ cells. 
L i k e w i s e ,  i t  h a s  b e e n  r e p o r t e d   that  surface  expression  of 
CD137 is absent on MDSCs (17). We also checked the IFNγ 
dependency  because  IFNγ-dependent,  anti-CD137-induced 
CD11b
＋Gr-1
＋  cell  expansion  was  reported  in  autoimmune 
disease  model  (6).  However,  under  normal  conditions  this 
phenomenon  was  not  found  (data  not  shown).  Thus,  it 
seemed  that  CD137  stimulation  indirectly  affected  CD11b
＋
Gr-1
＋ c e l l s  b y  a n  I F N γ-independent  pathway,  and  further 
studies  are  needed  to  define  the  mechanism  of  anti-CD137 
mAb  treatment  on  MDSC  induction. 
    MDSCs can suppress T cell proliferation and activation by 
secreting  iNOS,  arginase,  reactive  oxygen  species,  nitrating 
TCR and deprivating cysteine (16). Future studies should in-
vestigate whether CD11b
＋Gr-1
＋ cells induced by CD137 sig-
naling also use same suppression mechanisms as MDSCs or 
have  a  unique  system.
    Although  it  was  reported  that  anti-CD137  mAb-injected 
mice  developed  a  series  of  immunological  anomalies  (15), 
preliminary  results  from  ongoing  clinical  trials  using  the 
humanized anti-CD137 mAb in cancer patients showed that 
the toxicity profile in these patients was mild (18). However, 
there  is  also  the  possibility  that  these  newly  revealed  im-
munosuppressive  CD11b
＋Gr-1
＋  cells  could  be  observed  in 
anti-CD137 mAb-treated cancer patients and negatively impact 
immune responses. Thus, it is necessary to confirm whether 
this cell population could have significant implications in clin-
ical  settings.Myeloid-derived Suppressor Cells Induced by CD137 Stimulation
Jung-Mi Lee, et al.
107 IMMUNE NETWORK http://www.ksimm.or.kr Volume 10 Number 3 June 2010
Figure 3. Increased xCD11b
＋Gr-1
＋ cells by CD137 stimulation suppress T cell proliferation. Total splenocytes (4×10
5) of DO11.10 mice (A, 
C) or OT-I mice (B, D) were stimulated with OVA protein (A, C: 100μg/ml, B, D: 250μg/ml) and serially diluted naïve splenic CD11b
＋Gr-1
＋
cells or 3H3 induced CD11b
＋Gr-1
＋ cells (A, B: 5 days after 3H3 treatment; C, D: 25 days after 3H3 treatment) were added. Three days after
culture, T cell proliferation was examined including an 18 hr pulse with 4μCi/ml [
3H] thymidine.
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